Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: A prospective study

Transfusion

Volumn 50, Issue 2, 2010, Pages 354-360

  Martinez Saguer, Inmaculada ^a   Rusicke, Eva ^a   Aygören Pürsün, Emel ^a   Von Hentig, Nils ^a   Klingebiel, Thomas ^a   Kreuz, Wolfhart ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR;

ADULT; ANGIONEUROTIC EDEMA; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; MALE; PASTEURIZATION; PROSPECTIVE STUDY; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; ANGIOEDEMAS, HEREDITARY; AREA UNDER CURVE; BODY WEIGHT; CHILD; COMPLEMENT C1 INACTIVATOR PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 75749126152     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02394.x     Document Type: Article

References (27)

1. Quincke H. Über akutes umschriebenes Hautödem. Monatsh Prakt Dermatol 1882 5 : 129 31.
2. Osler W. Hereditary angioneurotic edema. Am J Med Sci 1888 95 : 362 7.
3. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992 71 : 206 15.
4. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006 119 : 267 74.
5. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 2008 359 : 1027 36.
6. Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000 75 : 349 54.
7. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976 84 : 580 93.
8. Goering HD, Bork K, Spaeth PJ, Bauer R, Ziemer A, Hinter H. Investigations of hereditary angioedema in German-speaking countries. Der Hautarzt 1998 49 : 114 22.
9. Bowen T, Cicardi M, Bork K, Zuraw B, Frank M, Ritchie B, Farkas H, Varga L, Zingale LC, Binkley K, Wagner E, Adomaitis P, Brosz K, Burnham J, Warrington R, Kalicinsky C, Mace S, McCusker C, Schellenberg R, Celeste L, Hebert J, Valentine K, Poon MC, Serushago B, Neurath D, Yang W, Lacuesta G, Issekutz A, Hamed A, Kamra P, Dean J, Kanani A, Stark D, Rivard GE, Leith E, Tsai E, Waserman S, Keith PK, Page D, Marchesin S, Longhurst HJ, Kreuz W, Rusicke E, Martinez-Saguer I, Aygoren-Pursun E, Harmat G, Fust G, Li H, Bouillet L, Caballero T, Moldovan D, Spath PJ, Smith-Foltz S, Nagy I, Nielsen EW, Bucher C, Nordenfelt P, Xiang ZY. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 2008 100 : S30 40.
10. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008 100 : 153 61.
11. Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997 99 : 194 6.
12. Hosea SW, Santaella ML, Brown EJ, Berger M, Katusha K, Frank MM. Long-term therapy of hereditary angioedema with danazol. Ann Intern Med 1980 93 : 809 12.
13. Bork K. Pasteurized C1 inhibitor concentrate in hereditary angioedema: pharmacology, safety, efficacy and future directions. Expert Rev Clin Immunol 2008 4 : 13 20.
14. Cicardi M, Zingale LC, Zanichelli A, Deliliers DL, Caccia S. The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema. Expert Opin Pharmacother 2007 8 : 3173 81.
15. Craig T, Levy R, Wasserman R, Bewtra A, Hurewitz D, Obtulowicz K, Reshef A, Kiessling P, Bernstein J. Treatment of hereditary angioedema with human C1 esterase inhibitor: results of a global, multicenter, randomised, placebo-controlled, phase II/III dose finding study of acute abdominal and facial attacks. XXVII Congress of the European Academy of Allergology and Clinical Immunology. Barcelona, Spain 2008.
16. Committee for Proprietary Medicinal Products. Note for guidance on the clinical investigation of plasma derived antithrombin products. European Agency for the Evaluation of Medicinal Products : Committee for Proprietary Medicinal Products 2002. CPMP/BPWG/2220/99. [monograph on the internet]. Available from: http://www.emea.europa.eu/pdfs/human/bpwg/222099en.pdf
17. Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962 51 : 224 32.
18. Berntorp E, Bjorkman S. The pharmacokinetics of clotting factor therapy. Haemophilia 2003 9 : 353 9.
19. Kunschak M, Engl W, Maritsch F, Rosen FS, Eder G, Zerlauth G, Schwarz HP. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998 38 : 540 9.
20. Kodama J, Uchida K, Nakayama R. Clinical effect of C1 inhibitor concentrate in patients with hereditary angioneurotic edema. Shinryo to Shinyaku 1987 24 : 2041 53.
21. Brackertz D, Isler E, Kueppers F. Half-life of C1INH in hereditary angioneurotic oedema (HAE). Clin Allergy 1975 5 : 89 94.
22. de Zwaan C, Kleine AH, Diris JH, Glatz JF, Wellens HJ, Strengers PF. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002 23 : 1670 77.
23. Diris JH, Hermens WT, Hemker PW, Lagrand WK, Hack CE, van Dieijen-Visser MP. Pharmacokinetics of C1-inhibitor protein in patients with acute myocardial infarction. Clin Pharmacol Ther 2002 72 : 498 504.
24. Quastel M, Harrison R, Cicardi M, Alper CA, Rosen FS. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest 1983 71 : 1041 6.
25. Woo P, Lachmann PJ, Harrison RA, Amos N, Cooper C, Rosen FS. Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases. Clin Exp Immunol 1985 61 : 1 8.
26. van Doorn MB, Burggraaf J, van Dam T, Eerenberg A, Levi M, Hack CE. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005 116 : 876 83.
27. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001 161 : 714 8.